Primary study · included by 1 review
Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy.
Burgard 2024 · Burgard Caroline, Khreish Fadi, Dahlmanns Lukas, et al. · Cancers · 2024
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
PSA decline of 50% or more (PSA50 response) [225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies) | Proportion (random-effects, REML) 0.47 [0.37, 0.56] | 8 studies · 323 participants | GRADE not reported |
PSA decline of 50% or more (PSA50 response) [225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies) | Proportion (random-effects, REML) 0.44 [0.32, 0.56] | 6 studies · 169 participants | GRADE not reported |
1 including review in total.